Vigil Neuroscience — JP Morgan Healthcare Conference 2024
31 slides from Vigil Neuroscience's conference presentation, Jan 11, 2024

Slide 1: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference January 11, 2024 © Vigil Neuroscience, Inc. 2024. All rights reserved. Ivana Magovčević-Liebisch, PhD, JD President & Chief Executive Officer Exhibit 99.1

Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact may be d

Slide 3: Vigil Neuroscience: A Clinical-Stage Microglia-Focused Therapeutics Company
Vigil Neuroscience: A Clinical-Stage Microglia-Focused Therapeutics Company Focused on treating rare and common neurodegenerative diseases by restoring vigilance of microglia, the brain’s sentinel immune cells Precision-based strategy for developing microglia therapeutics Only company known to have

Slide 4: Restoring Microglia with TREM2 as a Therapeutic Target
Restoring Microglia with TREM2 as a Therapeutic Target © Vigil Neuroscience, Inc. 2024. All rights reserved. Microglia sense and respond to damage signals and coordinate signal-specific downstream responses Microglial dysfunction is associated with rare and common neurodegenerative diseases TREM2 is

Slide 5: Vigil's Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases
Vigil’s Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases First Indication Rare Microgliopathy (ALSP) Data Driven Expansion in Other Rare Microgliopathies Pipeline Candidates for Genetically Defined Subpopulations in Common Indications (AD) Further Expansion into Broade

Slide 6: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities
Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities Iluzanebart (VGL101): TREM2 mAb in development for ALSP VG-3927: Small Molecule TREM2 Agonist in development for AD ONLY targeted drug candidate in clinical development for ALSP 1st & ONLY TREM2 small molecule agonist in clinical de

Slide 7: Building a Robust Pipeline in Rare & Common Neurodegenerative Diseases
Building a Robust Pipeline in Rare & Common Neurodegenerative Diseases Vigil has exclusive rights to all programs Alzheimer’s Disease Iluzanebart (VGL101): Fully Human Monoclonal Antibody Healthy Volunteer Phase 1 Trial1 (Completed) Healthy Volunteer VG-3927: Oral Small Molecule TREM2 Agonist Discov

Slide 8: Iluzanebart (VGL101) Antibody TREM2 Agonist for Treatment of ALSP
Iluzanebart (VGL101) Antibody TREM2 Agonist for Treatment of ALSP © Vigil Neuroscience, Inc. 2024. All rights reserved. Iluzanebart (VGL101) is an investigational therapy and has not been reviewed or approved by any regulatory authority

Slide 9: ALSP: A Genetically-linked Microgliopathy with Significant Unmet Need
Epidemiology 10% adult-onset leukodystrophies: Including ~10K patients in U.S. & ~15K patients in EU27+UK Monogenic Disease Autosomal dominant CSF1R gene mutations Clinical Phenotype Average age of onset in mid-40s Cognitive, neuropsychiatric and motor symptoms Commonly misdiagnosed Rapid Progressio

Slide 10: Validation: Iluzanebart Compensation of CSF1R Signaling Defect
Validation: Iluzanebart Compensation of CSF1R Signaling Defect Iluzanebart Rescues Microglial Deficiency Caused by CSF1R Mutations © Vigil Neuroscience, Inc. 2024. All rights reserved. IBA-staining; red arrows denote microglia - Berdowski et al. Acta Neuropath 2022 TREM2 Agonism via Iluzanebart Phar

Slide 11: Proof of target engagement and pharmacological activity in healthy volunteers
Proof of target engagement and pharmacological activity in healthy volunteers 1st antibody to report durable effect on microglial activity biomarkers in clinical setting Summary of Iluzanebart Phase 1 Data in Healthy Volunteers SAD: single ascending dose; MAD: multiple ascending dose; PK: pharmacoki

Slide 12: ILLUMINATE: First Natural History Study in ALSP
ILLUMINATE: First Natural History Study in ALSP ILLUMINATE: NCT05020743 © Vigil Neuroscience, Inc. 2024. All rights reserved. Ongoing natural history study of ALSP patients with CSF1R gene mutation Enrolling up to 50 subjects globally Observation period: 24 months To characterize MRI & CSF biomarker

Slide 13: Baseline Fluid Biomarker Levels Altered in ALSP
Baseline Fluid Biomarker Levels Altered in ALSP NfL levels highly elevated in symptomatic sTREM2 levels similar across all populations sCSF1R levels significantly reduced in prodromal and symptomatic sTREM2 concentration (pg/ml) 0 1000 2000 3000 4000 51 4 7 Healthy Prodromal Symptomatic sCSF1R conce

Slide 14: MRI Biomarkers of Disease Progression Precede Cognitive Decline
Gray Matter Volume Change from Baseline at Month 12 Montreal Cognitive Assessment (MoCA)* MoCA Change from Baseline Prodromal (11) Symptomatic (6) Cognitive Worsening 2 1 0 1 -2 -3 -4 MRI Biomarkers of Disease Progression Precede Cognitive Decline Plots are Mean ± SE * Montreal Cognitive Assessment:

Slide 15: MRI Biomarkers of Disease Progression Correlate with Cognitive Decline
MRI Biomarkers of Disease Progression Correlate with Cognitive Decline Worsening Worsening © Vigil Neuroscience, Inc. 2024. All rights reserved. Worsening Worsening Ventricular/Gray matter volume changes correlate with MoCA changes at 12 Months Prodromal Symptomatic Ventricular Volume Changes (mL) M

Slide 16: Evaluating Iluzanebart for ALSP in IGNITE Phase 2 Open-Label Proof-of-Concept Trial
Evaluating Iluzanebart for ALSP in IGNITE Phase 2 Open-Label Proof-of-Concept Trial © Vigil Neuroscience, Inc. 2024. All rights reserved. Follow up Trial Population Patients with symptomatic ALSP related to CSF1R gene mutation Trial Design Open-label, ~15 patients Treatment Duration 12 months (with

Slide 17: IGNITE Phase 2 Interim Readout: Favorable Safety & Tolerability Profile
IGNITE Phase 2 Interim Readout: Favorable Safety & Tolerability Profile Safety data summary Summary of Safety Outcomes (N=6)a Patients with TEAEs Any AE, n (%) 4 (66.7) Treatment-related AEs, n (%)b 2 (33.3) Mildc 2 (33.3) Moderatec 1 (16.7) Severe 0 Treatment-related AEs occurring in ≥2 participant

Slide 18: Emerging Patient Segments in IGNITE Phase 2 Interim Readout
Emerging Patient Segments in IGNITE Phase 2 Interim Readout NfL significantly higher than age-normal range MoCA <26 Significant neurodegeneration with cognitive impairment as one of ALSP symptoms NfL higher than age-normal range MoCA >26 Evidence of neurodegeneration Have other ALSP symptoms except

Slide 19: IGNITE Phase 2: Summary of Biomarker Changes
Progressive Disease Cognitively Normal Potentially Converting IGNITE Phase 2: Summary of Biomarker Changes 6-month interim analysis1 Patient1 Baseline NfL (pg/mL) Baseline MoCA ΔMRI Venticular2 ΔMRI Gray Matter2 ΔsCSF1R CSF3 ΔNfL Serum4 VGL101 Impact Based on Biomarker Changes A 80 17 Slowing progre

Slide 20: Positioning Iluzanebart for Potential Accelerated Development Pathway
Positioning Iluzanebart for Potential Accelerated Development Pathway Iluzanebart (VGL101) Target engagement with mechanistic link - iluzanebart increased sCSF1R levels (very low in untreated patients) Directionally supportive changes on MRI & NfL for iluzanebart in Ph2 MRI biomarkers correlating wi

Slide 21: VG-3927 Small Molecule TREM2 Agonist for Treatment of Alzheimer's Disease
VG-3927 Small Molecule TREM2 Agonist for Treatment of Alzheimer’s Disease © Vigil Neuroscience, Inc. 2024. All rights reserved.

Slide 22: Human Microglia Play a Central Role in Alzheimer's Disease
Human Microglia Play a Central Role in Alzheimer’s Disease (AD) Loss of TREM2 Function Worsens Neurodegeneration in AD Models TREM2 Small Molecule Agonist: Broad Potential to Reduce AD Pathology via Oral Dosing AD risk variants impair microglia clustering around Aβ plaques TREM2 deficiency is associ

Slide 23: VG-3927: First & Only Clinical-stage Small Molecule TREM2 Agonist
Increased Versatility Improved Safety VG-3927: First & Only Clinical-stage Small Molecule TREM2 Agonist VG-3927 Potential Differentiation Small molecule optimal for future combination therapy & preventive paradigms Wider therapeutic window: synergy with natural damage ligands ARIA mitigation & manag

Slide 24: VG-3927 Potentiates Signaling of Damage-associated Ligands
VG-3927 Potentiates Signaling of Damage-associated Ligands Focusing Efficacy in Pathological Microenvironments Plaque-burdened AD State Potentiation of TREM2 Activation VG-3927 Sulfatide Alone VG-3927 Alone VG-3927 + Sulfatide TREM2 Activation © Vigil Neuroscience, Inc. 2024. All rights reserved. Su

Slide 25: VG-3927 Protects Against Biomarkers of Inflammation-induced Neurodegeneration
VG-3927 Protects Against Biomarkers of Inflammation-induced Neurodegeneration ANOVATreatment, p<0.05 VG-3927 Suppresses Extracellular NfL & Tau Accumulation in LPS Model TREM2 Agonism Activates Anti-inflammatory Benefit VG-3927 Neuro- inflammation Neurodeg Stimulus LPS/IFNy Neurodegeneration Extrace

Slide 26: VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice
VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice VG-3927 Effects in Humanized TREM2 AD Mouse Model VG-3927 dosing initiated at ~5 months (plaque deposition already ongoing) Trend toward reducing plaque area and insoluble Aβ Daily Dosing for 6 Weeks VG-3927 10mpk QD Effects following 6 weeks of or

Slide 27: VG-3927: Early-Stage Clinical Strategy to De-Risk Development for AD
Ongoing Phase 1 SAD/MAD in healthy volunteers Exploring safety, tolerability, PK & PD PD biomarkers: sTREM2, sCSF1R & osteopontin Planned Phase 1b AD cohort Safety & tolerability PD in genetically-defined subpopulations (e.g., TREM2 variants) Identify AD subpopulation for future clinical trials Plan

Slide 28: Corporate Overview
Corporate Overview © Vigil Neuroscience, Inc. 2024. All rights reserved.

Slide 29: Achieved & Anticipated Milestones
Achieved & Anticipated Milestones Report VG-3927 interim Phase 1 data in healthy volunteers Mid-2024 © Vigil Neuroscience, Inc. 2024. All rights reserved. Report full data analysis for Phase 1 trial with iluzanebart in healthy volunteers Oct 2023 Q4 2023 Begin Phase 1 dosing of VG-3927 in healthy vo

Slide 30: Vigil is Well-positioned to Execute on Our Mission
Vigil is Well-positioned to Execute on Our Mission Our vision is a brighter tomorrow for people with devastating neurodegenerative diseases Microglial biology is rapidly becoming a new frontier for CNS drug discovery TREM2 deficiency leads to microglial dysfunction & drives neurodegeneration We are

Slide 31: Thank You
THANK YOU VIGILANT FOR YOU is a registered trademark of Vigil Neuroscience, Inc. VIGIL, VIGIL NEUROSCIENCE, VIGIL NEURO, and the VIGIL NEURO, ILLUMINATE and IGNITE logos are trademarks of Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2024. All rights reserved.
Source: SEC EDGAR · 8-K filed Jan 11, 2024
More decks from Vigil Neuroscience Inc
Technical Presentation (November 2023)56 slides · Nov 16, 2023
Technical Presentation (September 2023)71 slides · Sep 13, 2023
JP Morgan Healthcare Conference 202329 slides · Jan 9, 2023
Technical Presentation (December 2022)127 slides · Dec 6, 2022
Technical Presentation (November 2022)20 slides · Nov 2, 2022